Alimera Sciences, Inc. (NASDAQ:ALIM) has been given a $3.00 target price by analysts at Cowen and Company in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cowen and Company’s price target indicates a potential upside of 91.08% from the stock’s current price.

ALIM has been the topic of a number of other reports. Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They issued a “buy” rating and a $4.00 price target on the stock. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Finally, ValuEngine downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $3.38.

Alimera Sciences (NASDAQ ALIM) traded up 4.67% on Thursday, reaching $1.57. 382,253 shares of the company’s stock were exchanged. The firm’s market capitalization is $101.89 million. The stock’s 50 day moving average price is $1.42 and its 200 day moving average price is $1.38. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $2.40.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/06/alimera-sciences-inc-nasdaqalim-given-a-3-00-price-target-by-cowen-and-company-analysts.html.

A number of hedge funds have recently modified their holdings of the stock. Kennedy Capital Management Inc. purchased a new stake in shares of Alimera Sciences during the first quarter valued at $467,000. JW Asset Management LLC increased its stake in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. Finally, KCG Holdings Inc. increased its stake in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares in the last quarter. Hedge funds and other institutional investors own 43.58% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.